Literature DB >> 22963723

Primary pseudomyogenic haemangioendothelioma of bone.

W Q Sheng1, J Wang.   

Abstract

AIMS: Pseudomyogenic haemangioendothelioma is a recently described vascular neoplasm that occurs most commonly in the soft tissue of distal extremities of young adults. Occurrence outside the somatic soft tissue has not been described thus far. We present here a unique case of pseudomyogenic haemangioendothelioma that arose in the long tubular bones of the lower extremity. METHODS AND
RESULTS: The initial open biopsy was interpreted as a fibrous histiocytoma. However, the curettage specimen showed prominent epithelioid cytomorphology with a striking rhabdomyoblast-like appearance. By immunohistochemistry, the linear membranous staining of CD31 was highly suggestive of endothelial differentiation of the tumour cells.
CONCLUSIONS: To the best of our knowledge, this case represents the first example of primary pseudomyogenic haemangioendothelioma of bone. Clinical and pathological correlation with application of immunohistochemistry is mandatory in establishing the correct diagnosis and excluding tumours with overlapping features.
© 2012 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22963723     DOI: 10.1111/j.1365-2559.2012.04347.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  The clinicopathological spectrum of pseudomyogenic hemangioendothelioma: report of an additional series with review of the literature.

Authors:  Yuefang Sun; Ming Zhao; I Weng Lao; Lin Yu; Jian Wang
Journal:  Virchows Arch       Date:  2020-01-24       Impact factor: 4.064

Review 2.  An aggressive case of pseudomyogenic haemangioendothelioma of bone with pathological fracture and rapidly progressive pulmonary metastatic disease: case report and review of the literature.

Authors:  Asad Rabbani Shah; Malee Fernando; Rachel Musson; Nikhil Kotnis
Journal:  Skeletal Radiol       Date:  2015-05-17       Impact factor: 2.199

3.  A novel treatment for bone lesions of multifocal epithelioid sarcoma-like hemangioendothelioma.

Authors:  Adrian T Davis; A Mary Guo; Nancy J Phillips; David D Greenberg
Journal:  Skeletal Radiol       Date:  2015-01-08       Impact factor: 2.199

4.  Giant cell angioblastoma of bone: four new cases provide further evidence of its distinct clinical and histopathological characteristics.

Authors:  Lin Yu; I Weng Lao; Jian Wang
Journal:  Virchows Arch       Date:  2015-03-28       Impact factor: 4.064

5.  Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions.

Authors:  Narasimhan P Agaram; Lei Zhang; Paolo Cotzia; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-12       Impact factor: 6.394

6.  Primary pseudomyogenic haemangioendothelioma of bone: report of two cases.

Authors:  Alberto Righi; Marco Gambarotti; Piero Picci; Angelo Paolo Dei Tos; Daniel Vanel
Journal:  Skeletal Radiol       Date:  2014-10-11       Impact factor: 2.199

Review 7.  Pseudomyogenic hemangioendothelioma with bone and soft tissue involvement with favorable response to pamidronate: a case report and systematic review of the literature.

Authors:  María Lorena Brance; Nicolás M Cóccaro; Pablo Roitman; Alejandro Castiglioni; Florencia Agostinis; Mariel Spense; Bárbara Scheitlin; Nicholas Rene; Lucas R Brun
Journal:  Arch Osteoporos       Date:  2022-02-01       Impact factor: 2.617

8.  Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report.

Authors:  Shinya Otani; Robert Nakayama; Tetsuya Sekita; Toru Hirozane; Naofumi Asano; Kazumasa Nishimoto; Aya Sasaki; Hajime Okita; Hideo Morioka; Masaya Nakamura; Morio Matsumoto
Journal:  BMC Cancer       Date:  2019-09-03       Impact factor: 4.430

9.  Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma.

Authors:  Jason Joseph; Wei-Lien Wang; Madhavi Patnana; Naveen Ramesh; Robert Benjamin; Shreyaskumar Patel; Vinod Ravi
Journal:  Clin Sarcoma Res       Date:  2015-10-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.